2026-09-25 日報 ⌂

🩺 醫藥健康每日摘要 - 第 244 期 (2026-09-25)

重點導讀

1. 更多快速動眼期睡眠與 83 種疾病風險降低相關 (More REM sleep linked to lower risk of 83 diseases)

這項大型研究追蹤了超過 95,000 人,首次揭示快速動眼期(REM)睡眠時間較長與 83 種疾病(包括失智症、心臟衰竭及帕金森氏症)的較低風險有關。這項發現對於理解睡眠機制與慢性病預防具有重大意義,可能引導未來針對睡眠模式干預的健康策略。

2. 突破性藥物逆轉皮膚老化並顯著加速傷口癒合 (Breakthrough drug reverses skin aging and dramatically speeds healing)

一款局部用藥透過清除老化、受損細胞,顯著加速了老年小鼠的皮膚傷口癒合。此療法似乎重新啟動了炎症、膠原蛋白生成和新血管生長等修復途徑,預示著在抗衰老和傷口護理領域的巨大潛力。

3. GLP-1 減重與糖尿病藥物恐導致近六分之一兒童營養缺乏 (GLP-1 weight loss and diabetes drugs linked to nutritional deficiencies in nearly 1 in 6 children)

一項新研究指出,服用 GLP-1 類藥物(如 Victoza, Saxenda, Trulicity, Ozempic)用於體重控制或糖尿病的兒童,近六分之一在一年內被診斷出營養缺乏,其中維生素 D 缺乏症影響約 12%。這突顯了對這些廣泛使用藥物在兒童群體中潛在副作用的忽視,提示臨床醫師需加強監測與營養補充。

4. FDA 批准 Belzutifan 聯合 Lenvatinib 治療晚期透明細胞腎細胞癌 (FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component)

美國食品藥物管理局(FDA)批准了 belzutifan (Welireg) 聯合 lenvatinib (Lenvima) 用於治療晚期透明細胞腎細胞癌(ccRCC)成人患者。這項批准為這類難治性癌症患者提供了新的治療選擇,有望改善其預後。

5. FDA 專家小組在疑慮下仍勉強支持多癌血液檢測 (FDA panel narrowly backs multi-cancer blood test despite doubts it works)

美國 FDA 顧問委員會雖對一種旨在檢測 50 多種癌症的血液篩檢方法的有效性存有疑慮,但仍以微弱優勢支持該檢測。這項決定反映了對早期癌症篩檢潛力的期待與對其確切臨床效益證據不足的權衡。

6. 美國 FDA 批准禮來藥廠每週一次胰島素注射劑用於第二型糖尿病 (US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes)

美國 FDA 已批准禮來藥廠開發的每週一次胰島素注射劑用於治療第二型糖尿病。這項新藥的獲批為患者提供了更便捷的治療方案,有望提高依從性並改善血糖控制。

7. FDA 局長被提名人海蒂·歐弗頓面對參議院質詢,旨在加速醫學研究並應對中國崛起 (FDA commissioner nominee Heidi Overton faces questions at Senate hearing, aims to speed up medical research, combat China’s rise)

川普總統提名的 FDA 局長人選海蒂·歐弗頓博士在參議院聽證會上回答了有關疫苗、墮胎藥、食品安全等關鍵問題。她闡明將致力於加速醫學研究和應對中國在全球醫療領域日益增長的影響力,這將對未來的藥物審批和公共衛生策略產生深遠影響。

精細分類

Evidence (實證醫學)

  • 回應:當代更年期荷爾蒙療法與血栓性疾病:全國巢式病例對照研究 (Re: Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study)

    這篇文章是對一項關於更年期荷爾蒙療法與血栓性疾病關聯的全國性巢式病例對照研究的回應。讀者信件通常會對原始研究的方法論、結論或潛在偏差提出意見,為學術討論與證據完善提供平台。

  • 澄清目標試驗估計量及其在器官捐贈決策中的應用 (Clarifying the target trial estimand and its application to organ-offer decisions)

    此回應文章感謝原作者強調了目標試驗估計量的應用重要性,特別是在器官捐贈決策情境中。這類討論有助於精確定義臨床研究的目標,確保研究結果的適用性和可解釋性,對於實證醫學的嚴謹性至關重要。

  • 回應:撲熱息痛(對乙醯氨基酚)中毒的處理 (Re: Management of paracetamol (acetaminophen) toxicity)

    這是一篇關於撲熱息痛(acetaminophen)中毒處理的文章回應,旨在探討和澄清其管理策略。該回應可能對現有指南提出補充意見或質疑,以期優化臨床實踐中對撲熱息痛中毒患者的治療方案。

  • 回應:CONSORT-兒童與青少年 (CONSORT-C) 2026:讓患者在解釋研究中發聲 (Re: CONSORT-Children and Adolescents (CONSORT-C) 2026 : giving patients a voice in interpreting research.)

    此篇文章回應了 CONSORT-兒童與青少年指南,特別強調了讓患者,尤其是兒童與青少年,在解釋臨床研究結果時擁有發言權的重要性。這有助於提升研究的倫理標準與實用性,確保研究成果能真實反映患者需求與經驗。

  • 回應:失智症:臨床醫師支持全國失智症診斷目標及減輕失智風險的目標 (Re: Dementia: Calls for national target for dementia diagnosis backed by clinicians and a target for mitigating risk of dementia)

    該回應文章支持建立失智症的及時診斷國家目標,並強調除了診斷外,設定減輕失智症風險的目標同樣重要。這代表了在失智症防治策略上,不僅要早期發現,更要積極介入風險因子,以提升整體公共衛生效益。

  • 紅血球輸注治療或預防鐮狀細胞病併發症:Cochrane 綜述概述 (Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews)

    此 Cochrane 綜述概述了紅血球輸注在治療或預防鐮狀細胞病併發症方面的證據。它綜合分析了多項研究結果,為臨床醫師提供了關於輸血治療有效性和安全性的實證依據,有助於指導鐮狀細胞病的臨床管理。

Clinical (臨床研究與應用)

Guideline (醫療指引與政策)

Pharma (藥物研發與產業)

AI Medicine (AI 醫療應用)

Public Health (公共衛生)

Nutrition & Lifestyle (營養與生活型態)

其他未分類

  • 廣東話是「中文」還是「方言」?從台灣台語定位,反思語言的界線 (Is Cantonese a "Chinese language" or a "dialect"? Reflecting on language boundaries from the status of Taiwanese Hokkien)

    日本語言學者飯田真紀指出,一種語言的地位不只取決於相似度,更與其使用地域、教育和公共領域的影響有關。廣東話的案例鮮明地展示了「地點一改變,地位也隨之改變」的語言特性,引發對語言本質和社會定位的反思。

  • RFK Jr. 的道德申報揭露數百萬美元的書籍交易 (RFK Jr.'s ethics filing reveals book deals worth millions of dollars)

    衛生部長小羅伯特·F·甘迺迪(RFK Jr.)的年度財務披露顯示,他在任職期間獲得了兩筆豐厚的書籍預付款和來自朋友的免費航班。這項消息引發了對官員利益衝突和道德規範的關注,為公眾提供了審視其財務狀況的機會。

  • 貧困夫婦獲得現金和支出計畫。結果有好有壞 (Needy couples got cash and a spending plan. Results were good -- and bad)

    在賴比瑞亞,一項向貧困夫婦提供現金援助和共同財務規劃的計畫,在帶來益處的同時,也對部分家庭產生了意外的負面影響。這項研究揭示了現金轉移專案在社會經濟背景下可能產生的複雜後果,尤其是在伴侶間關係方面的影響。


English Daily Highlights

Today's medical and health news brings several significant developments across clinical research, public health, and regulatory affairs. A major finding from Science Daily reveals that more time spent in REM sleep is linked to a lower risk of 83 diseases, including dementia and heart failure, suggesting profound implications for sleep health and disease prevention. Another promising report highlights a breakthrough topical drug that reverses skin aging and dramatically accelerates wound healing in older mice by reactivating repair pathways, offering new hope for dermatology and regenerative medicine.

On the pharmaceutical front, a critical study warns that GLP-1 medications for weight loss and diabetes may lead to nutritional deficiencies in nearly one in six children, urging closer monitoring and nutritional support for young patients on these drugs. The FDA has made two key approvals: belzutifan in combination with lenvatinib for advanced renal cell carcinoma, providing a new option for a challenging cancer, and Lilly's once-weekly insulin injection for type 2 diabetes, which could enhance patient adherence and blood sugar control.

Regulatory discussions are also in focus, with the FDA panel narrowly endorsing a multi-cancer blood test despite lingering doubts about its efficacy. This decision underscores the tension between innovation and robust evidence in diagnostic tools. Furthermore, President Trump's nominee for FDA commissioner, Heidi Overton, faced Senate questioning, outlining her priorities to accelerate medical research and counter China's influence in global healthcare, which will shape future drug regulation and public health strategies. In other policy news, the White House's controversial plan to exert greater control over NIH grants appears to be "dead," easing concerns about political interference in biomedical research funding.

Public health issues include a doctor's personal reflection on surviving measles, emphasizing the critical importance of vaccination amidst rising hesitancy. Food safety alerts were issued for undeclared allergens in pasta and elevated lead levels in cinnamon seasoning, highlighting ongoing consumer protection efforts. Globally, the UN reported that violence in Yemen has struck refugee camps and health centers, pointing to a dire humanitarian and public health crisis.

Lastly, in AI medicine, the collaboration between Cigna Group and OpenAI to support complex conditions, starting with cancer patients, showcases AI's potential in personalized care. However, the financial implications of AI tools are also being debated, with Blue Cross insurers reporting nearly $1 billion in extra costs, raising questions about the true cost-effectiveness and reimbursement models for AI in healthcare.